284P Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease.

Autor: Stativko, O.¹ (AUTHOR), Pokataev, I.¹ (AUTHOR), Fedyanin, M.² (AUTHOR), Kravchuk, D.A.² (AUTHOR), Andreiashkina, I.³ (AUTHOR), Polshina, N.³ (AUTHOR), Volkonskiy, M.V.⁴ (AUTHOR), Bystrov, A.⁴ (AUTHOR), Salpagarov, N.⁵ (AUTHOR), Antonova, T.¹ (AUTHOR), Zhukova, L.³ (AUTHOR), Volkova, M.I.¹ (AUTHOR), Stroyakovskiy, D.⁴ (AUTHOR), Galkin, V.N.⁶ (AUTHOR)

Publikováno v: Annals of Oncology. 2024 Supplement 4, Vol. 35, pS1514-S1515. 2p.